NEW YORK, Jan. 29 (UPI) --Community alum Danny Pudi says Season 4 of Mythic Quest, premiering on Apple TV+ Wednesday, will show a softer side of his conniving character Brad. Co-starring Rob ...

Spoiler alert! We're discussing important plot points and the ending of “Onyx Storm” by Rebecca Yarros (out now), so beware if you haven’t read it. Seriously, stop reading here if you don't ...

You can save this article by registering for free here. Or sign-in if you have an account. In the fifteen months since October 7, an absence of leadership has turned Toronto into a city that many ...

To the editor: So, David Steiner’s concrete home is the sole survivor in a destroyed Malibu neighborhood. I find that predictable, but apparently insurance companies don’t. My home is an ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

France's Macron wants more young volunteers 'to reinforce' the army In his New Year's address to the armed forces, President Emmanuel Macron called for a revision of France's military strategy ...

The UK must prepare for the arrival of superbugs that have already emerged from the battlefield in Ukraine, an MP has warned. Liberal Democrat Danny Chambers said the antimicrobial resistant ...

FDA approves Spravato as the first monotherapy for adults with major depressive disorder unresponsive to two oral antidepressants. In clinical trials, 22.5% of Spravato patients achieved remission ...

The Boston Bruins have made some surprising decisions, including making Brad Marchand a healthy scratch late in the game. This season has been a rollercoaster for the Boston Bruins thus far ...

Is Brad Marchand approaching his last miles in Boston? It seems unlikely to think of that situation since Marchand is so identified with the Bruins. But increasingly, in the community, the ...

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ...